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intravenous heparin-calcium again. Catheterization of the
right side of the heart 8 days later showed elevated pulmonary
artery pressures (45/25 mm Hg) and a mean pulmonary cap-
illary wedge pressure of 25 mm Hg. A subsequent transtho-
racic echocardiogram demonstrated subtotal thrombosis of
the mitral valve with a spherical thrombus adjacent to the
ventricular side of the prosthetic mitral valve (Fig 1) and
severely decreased occluder motion. At that time, platelet
counts had decreased from 287 · 109/L on admission to
156 · 109/L. Heparin-dependent antibodies were detected by
heparin/platelet factor 4 enzyme-linked immunosorbent
assay. Therefore heparin-calcium was instantaneously
replaced with the recombinant hirudin lepirudin (Refludan;
Hoechst Marion Roussel, Germany). Immediately before the
operation, a loss of the right radial and brachial artery pulses
occurred, suggestive of peripheral embolization. 
The patient underwent extracorporeal circulation at
hypothermia (28°C) and cardioplegic arrest during which an
ecarin clotting time assay was used to monitor anticoagula-
tion with lepirudin. Besides multiple thrombi in the left atri-
um, the mitral valve prosthesis was almost completely
obstructed with thrombus (Fig 2). The thrombotic formation
on the ventricular side of the prosthetic valve had disap-
peared. The prosthesis and the thrombotic material were
removed and a new mitral prosthesis was implanted (29 mm
St Jude Medical). After extracorporeal circulation, right
Heparin-induced thrombocytopenia (HIT) type II is one of
the most devastating but least widely recognized complica-
tions of heparin therapy. It is characterized by the tendency to
cause thrombocytopenia with associated thrombosis.1 The
condition typically arises between the 5th and 14th days after
first exposure to heparin therapy and is usually associated
with a platelet count below 100 · 109/L or a fall of platelet
counts to more than 50% of the baseline value accompanied
by heparin-induced antiplatelet antibodies. These patients are
at high risk for severe, mainly venous thromboembolic com-
plications with a mortality of up to 30%. The true incidence of
HIT type II is uncertain. A recent report including 332
patients receiving unfractionated heparin found an incidence
of 2.7%.2 The purpose of this case report is to alert cardiac
surgeons to the risk of cardiac prosthetic valve thrombosis in
patients treated with heparin and HIT. 
Clinical summary. A 58-year-old woman with a history of
mitral and aortic valve replacement in 1975 (Björk-Shiley 21
and 29 mm valves, Shiley, Inc, Irvine, Calif) and aortic valve
re-replacement (St Jude Medical 23 mm valve, St Jude
Medical, Inc, St Paul, Minn) and tricuspid ring annuloplasty
(Carpentier-Edwards ring size 34, Baxter Healthcare Corp,
Irvine, Calif) in 1991, underwent elective cholecystectomy.
Anticoagulant therapy with phenprocoumon (Marcumar;
Roche, Germany) was suspended before the operation and
switched to intravenous unfractionated heparin-calcium
(Calciparin; Sanofi Winthrop, Germany). After the unevent-
ful operation, phenprocoumon was restarted overlapping with
intravenous heparin-calcium until an international normal-
ized ratio of 3.0 was reached. Two months later she was read-
mitted to the cardiology department because of persistent
angina pectoris and electrocardiographic signs of anterolater-
al ischemia. Function of the aortic and mitral prosthetic
valves was normal without signs of thrombosis, as shown in
the transthoracic echocardiogram. Oral anticoagulant therapy
with phenprocoumon was stopped and the patient received
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Fig 1. Transthoracic echocardiography (apical 4-chamber
view) demonstrating spherical thrombus (arrow) attached to
the ventricular side of the mitral valve prosthesis. LV, Left ven-
tricle; LA, left atrium; RV, right ventricle; RA, right atrium.
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brachial artery embolectomy was performed and revealed a
“white clot.” The histomorphologic examination of the throm-
botic material showed a structure similar to onion skin with
markedly decreased fibrin content resulting in a loose and
wide-meshed fibrin web. Immunohistochemical staining
revealed markedly decreased fibrin content and a high amount
of immunoglobulin G. 
The patient recovered well from the operation. The postop-
erative blood loss was 1120 mL in the first 5 hours and 130
mL in the next 15 hours. On the first postoperative day the
chest drains were removed. She was further treated with lep-
irudin, which was later replaced with phenprocoumon.
Platelet counts returned to normal values on the 6th postop-
erative day and we observed no further thromboembolic
event. On the 20th postoperative day she was discharged
home. 
Conclusions. This case report clearly demonstrates the
urgent need for rapid recognition of HIT, because this side-
effect of heparin therapy may lead to severe, life-threatening
thromboembolic complications. Given the large number of
patients with coronary artery disease or valvulopathies under-
going cardiovascular operations and concomitant heparin
therapy, close monitoring of platelet counts is mandatory. A
drop of platelet counts below 100 · 109/L or to more than
50% of baseline values is highly suggestive of the presence of
heparin-induced antibodies, which should be confirmed by
laboratory testing. We observed a 46% decrease of platelet
counts in our patient on the 9th day of heparin treatment,
accompanied by a severe thrombosis of the mechanical mitral
valve prosthesis. So far there is no evidence that re-exposure
to heparin therapy leads to earlier formation of heparin-
induced antibodies and respective clinical manifestation of
HIT. However, Warkentin and associates2 reported on 2
patients in whom neurologic symptoms and thrombocytope-
nia developed shortly after re-exposure to heparin, indicating
that these patients may have been sensitized.3 HIT may
develop sooner after institution of therapy in patients pre-
exposed to heparin than in those receiving heparin for the first
time, suggestive of an anamnestic response.4 However,
almost all of these reported events have occurred within days
to weeks of the index exposure, when the heparin-induced
immunoglobulin G was still detectable in the circulation. Our
patient received intravenous heparin within this time frame
before the manifestation of HIT. Therefore we cannot exclude
the presence of a heparin-induced antibody on admission and
re-exposure to heparin. On the other hand, thrombocytopenia
and clinical manifestation of HIT did not develop earlier,
consistent with a primary immune response and absence of
immunologic memory. 
Any thromboembolic complication during heparin therapy
should prompt the clinician to exclude HIT, since heparin-
related thrombosis may occur despite normal platelet counts5
or precede thrombocytopenia in up to 30% of cases.6
Furthermore, patients with a mechanical valve prosthesis and
HIT may be at high risk for local thrombotic complications
since platelet activation, adhesion, and aggregation caused by
contact of platelets to artificial surfaces may be enhanced in
the presence of heparin-induced antibodies. Although these
patients require sustained parenteral anticoagulation either
due to their underlying disease or due to the acquired throm-
botic complications, immediate heparin cessation is obligatory.
Therefore alternative anticoagulants, such as low-molecular-
weight heparin, heparinoids, argatroban (a small-molecule,
reversible, direct thrombin inhibitor), and recombinant
hirudin, as well as several other drugs, have been introduced
in the treatment of patients with HIT. Low-molecular-weight
heparin and heparinoids resemble heparin’s immunologic
structure and can cross-react with the HIT antibody. In con-
Fig 2. Mitral valve prosthesis (Björk-Shiley 29 mm) showing almost complete thrombosis. Note the “white
thrombus” at 8 hours. 
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trast to these agents, argatroban and lepirudin bear no struc-
tural or immunologic resemblance to heparin and therefore
cannot induce platelet aggregation through HIT antibodies.3
Lepirudin is the most potent and specific thrombin inhibitor
currently known and is actually manufactured for clinical
purposes in a recombinant technique. It acts directly on
thrombin, blocking its complete catalytic activity indepen-
dently of cofactors such as antithrombin III. Therefore thera-
py with lepirudin seemed reasonable in our patient and pro-
vided sufficient anticoagulation, minimizing the risk of
further thromboembolic complications caused by the pres-
ence of heparin-induced antibodies. It should be pointed out
that neither the activated partial thromboplastin time nor the
activated clotting time is suitable for monitoring lepirudin as
an anticoagulant in extracorporeal circulation.7 However, the
ecarin clotting time assay used in our patient during car-
diopulmonary bypass allowed safe surveillance of the antico-
agulant activity of lepirudin.
There is no antidote for lepirudin. Moreover, patients with
renal insufficiency or acute renal failure are at high risk for an
accidental overdose, because lepirudin is eliminated predom-
inantly via the kidneys. Therefore treatment of bleeding com-
plications in these patients may be problematic. Despite that,
we did not observe any major bleeding in our patient.
To the best of our knowledge this may be the first report of
a severe mechanical valve thrombosis in a patient with
proven HIT. The clinical course of our patient underscores
the importance of close monitoring of platelet counts, as well
as immediate cessation of heparin therapy in the face of
thromboembolic complications, and laboratory approval of
heparin-induced antibodies.
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